DBV Technologies (NASDAQ:DBVT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Monday morning. The brokerage issued a hold rating on the stock.

DBVT has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of DBV Technologies in a report on Thursday, August 1st. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Trading Up 23.1 %

Shares of NASDAQ DBVT opened at $0.84 on Monday. DBV Technologies has a 12-month low of $0.50 and a 12-month high of $2.28. The firm’s 50-day moving average price is $0.78 and its 200-day moving average price is $0.96. The stock has a market capitalization of $80.81 million, a price-to-earnings ratio of -1.00 and a beta of 0.67.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative net margin of 638.21% and a negative return on equity of 74.41%. The business had revenue of $1.16 million for the quarter, compared to analysts’ expectations of $1.42 million. During the same quarter in the previous year, the firm earned ($0.26) EPS. On average, equities analysts predict that DBV Technologies will post -1.43 EPS for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. boosted its position in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies comprises about 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest position. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. Institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.